A gene therapy for multiple myeloma that was approved in the US in March has now been recommended for a conditional marketing authorisation by the European Medicines Agency. Abecma (idecabtagene vicleucel) is a chimeric antigen receptor (CAR) T cell therapy targeting the B cell maturation antigen (BCMA), a cell membrane receptor expressed exclusively on late stage B cells and plasma cells.
